Prospective Pilot Study Of The Effect Of Rifaximin On B-cell Dysregulation In Cirrhosis Due To Chronic Hepatitis C Infection
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2016
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 20 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2017.